Locally produced mucosal IgG in chickens immunized with conventional vaccines for Newcastle disease virus
AUTOR(ES)
Chimeno Zoth, S., Gómez, E., Carrillo, E., Berinstein, A.
FONTE
Brazilian Journal of Medical and Biological Research
DATA DE PUBLICAÇÃO
2008-04
RESUMO
Newcastle disease virus (NDV) is the causative agent of an economically important disease, which affects all species of birds worldwide. Current vaccination programs for NDV include the use of either low-virulent live-virus vaccines or inactivated vaccines to induce protective immunity while producing minimal adverse effects in birds. In order to further characterize the immune response elicited by live virus and inactivated NDV conventional vaccines in chickens, we evaluated the presence of specific antibodies in different secretions and in tissue culture supernatants of immunized birds. To this end, we analyzed all the samples by ELISA, using an indirect assay set up in the laboratory. Specific anti-NDV IgG antibodies were detected in tracheal and cloacal swabs and tracheal and intestinal washes of immunized animals. We also found specific anti-NDV IgG antibodies in tracheal and intestinal tissue culture supernatants, indicating that the IgG found in swabs and washes was not transudated from serum or, at least, was not all transudated from serum. Knowledge about the mechanisms involved in the immune response of chickens to different NDV vaccines should increase our understanding of the mucosal response against the virus and, eventually, provide new useful information for the development and evaluation of synthetic vaccines.
Documentos Relacionados
- IgG1 and IgG2 immunoglobulins to Bacteroides (Fusiformis) nodosus protease in infected and immunized sheep.
- Raised IgG antiglobulin factors in Still's disease.
- An IgG subclass imbalance in connective tissue disease.
- Catabolism of human serum IgG in health, rheumatoid arthritis, and active tuberculous disease. Possible influence of IgG structure.
- Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity.